Bandhan Bank Share Price: Q1 FY27 Profit Up 35% Amid RoA Guidance Cut

Key Takeaways

• Bandhan Bank share price moved sharply after Q1 FY27 results.
• Q1 FY27 net profit rose to Rs 502 crore, up 35% YoY; operating profit fell 19%.
• NII rose 6% YoY to Rs 2,920 crore; NIM declined 16 bps to 6.2%.
• RoA guidance for FY27 was cut to 1.2-1.4%, with analysts offering mixed targets.

Bandhan Bank share price has been volatile after the Q1 FY27 numbers, with shares slipping 15% to Rs 177.50 on the NSE. The lender posted Q1 FY27 net profit of Rs 502 crore, up 35% year‑over‑year, while costs rose sharply on higher staff expenses from the new labour policy and a 65% surge in technology outlay following the West Asia crisis. The combination of stronger profit and higher expenditure led management to trim the FY27 RoA guidance and to adopt a cautious external outlook.

The quarterly numbers show a mixed bag: Profit grew, but the edge in margins faded as cost pressures rose. Here is a quick snapshot of the Q1 FY27 results and where the bank stands going into the next quarter.

Metric	Q1 FY27	YoY Change
Net Profit	Rs 502 crore	Up 35%
Operating Profit	Rs 1,358 crore	Down 19%
Provisions	Rs 683 crore	Down 41%
NII	Rs 2,920 crore	Up 6%
NIM	6.2%	Down 16 bps
bandhan bank npa	End-June 3.15%	vs 4.96% a year ago
RoA Guidance For FY27	1.2-1.4%	From 1.6-1.8%

MD and CEO said that higher staff costs due to the new labour framework, and a 65% rise in technology costs after the West Asia crisis, pushed expenditures higher. Yet, lower credit cost supported the quarterly net profit. This nuance matters for those tracking the bandhan bank share price because it signals that growth remains intact but cost control will determine the margin path.

Analyst commentary across firms highlighted a cautious stance on FY28 margins and funding costs, even as some metrics beat estimates. Nomura noted that about 30 basis points of the 40 basis points of expected NIM expansion was pulled back, with the rest attributed to higher tech costs. The bank still sees a target of around Rs 190 for the stock, with a Neutral stance. CLSA described the quarter as decent but with a cautious management outlook, while noting NII beat expectations and the FY27 exit ROA target was cut to 1.2-1.4%. Jefferies has a Buy rating and a target of Rs 240, implying upside. Macquarie is Underperform with a target of Rs 130. Nuvama has a Hold with Rs 230; JPMorgan is Neutral at Rs 175.

On the price action side, the stock’s intraday move put it at the 15% lower circuit, marking the sharpest intraday decline since the Covid-era crash. The market is weighing the earnings strength against external headwinds, including macro uncertainty and deposit pricing pressures.

For deeper research that adapts to changing market conditions, consult Swastika's Sarthi AI stock assistant.

Bandhan Bank Share Price Reaction To Q1 FY27 Results And RoA Outlook

Bandhan Bank share price moves are shaping market expectations as investors parse a profit beat against higher costs and a revised RoA target. The 15% drop on the results day underscores concerns about margin resilience even as the top-line strength persists.

Bandhan Bank Results: Q1 FY27 Profit Up 35% But Costs Rise

Q1 FY27 results show Rs 502 crore net profit, up 35% YoY, with operating profit at Rs 1,358 crore, down 19% YoY. Provisions fell 41% YoY to Rs 683 crore. NII rose 6% YoY to Rs 2,920 crore, while NIM compressed 16 bps to 6.2%. End-June gross NPA stood at 3.15% vs 4.96% a year earlier, indicating improved asset quality. The RoA guidance was slashed to 1.2-1.4% for FY27 from the prior 1.6-1.8% range by the exit of Q4 FY27, reflecting higher funding costs and a cautious external environment.

Bandhan Bank NPA Trends And Asset Quality Improvement In Q1 FY27

End-June gross NPA decreased to 3.15% from 4.96% a year ago, signaling improved asset quality even as growth remains under pressure from competitive deposit pricing. The bandhan bank npa trend suggests that provisioning costs could remain elevated in the near term depending on macro trends and recoveries.

Analyst Views And Price Targets After Bandhan Bank Q1 FY27

Analysts remain divided about the stock's fair value and the near-term trajectory. Nomura has a Neutral rating with a target of Rs 190; CLSA has an Outperform view with a target of Rs 235; Jefferies shows a Buy rating with a target of Rs 240. Macquarie is Underperform with a target of Rs 130; Nuvama has a Hold with Rs 230; JPMorgan is Neutral at Rs 175. These varied calls reflect differing assumptions around NIM recovery, funding costs, and the pace of operating leverage.

Bandhan Bank Share Price And Market Valuation: What It Means For Investors

The mixed earnings narrative suggests the bank's growth could accelerate if margins stabilize and funding costs ease, but the near-term price action implies risk aversion among retail investors. Investors need to weigh the combination of profit growth against the rising expenditure and the revised FY27 RoA path, and to decide how much of the improvement in NII is sustainable. The stock's current price implies a re-rating risk if RoA and NIM stabilization fails to materialize. For deeper research that can adapt to changing market conditions, consult Swastika's Sarthi AI stock assistant.

Frequently Asked Questions

What were Bandhan Bank's Q1 FY27 results in terms of net profit and YoY change?

Q1 FY27 net profit was Rs 502 crore, up 35% YoY from Rs 372 crore in the same period a year earlier.

What were the key components of Bandhan Bank's Q1 FY27 results?

Provisions were Rs 683 crore (down 41% YoY); Operating profit Rs 1,358 crore (down 19% YoY); NII Rs 2,920 crore (up 6% YoY); NIM 6.2% (down 16 bps); End-June gross NPA 3.15% (vs 4.96% a year ago).

What is Bandhan Bank's RoA guidance for FY27 after the quarter?

RoA guidance was revised to 1.2-1.4% for FY27 from 1.6-1.8%.

How did external analysts react to Bandhan Bank's results?

Analysts issued varied targets and ratings: Nomura ₹190 Neutral; CLSA ₹235 Outperform; Jefferies ₹240 Buy; Macquarie ₹130 Underperform; Nuvama ₹230 Hold; JPMorgan ₹175 Neutral.

What happened to Bandhan Bank's stock price on the results day?

Shares hit the 15% lower circuit, slipping to around Rs 177.50, reflecting concerns about margin resilience despite profit growth.

Conclusion

Bandhan Bank's Q1 FY27 results reveal both resilience and the headwinds that quantify the near-term trajectory for the bandhan bank share price. Profit growth is real (Rs 502 crore) but margin drivers face cost pressures that will require sharper cost control and a steadier funding environment to sustain NII expansion. Retail investors should watch for the rate of margin recovery and the pace of loan growth as external conditions shift, particularly in energy and supply chain dynamics.

Open your trading and demat account here

Reference :

1 : Economictimes

Key Takeaways

• bluestone share price jumped 43% in two trading days as investor optimism grew around store expansion and solid Q1FY27 results.
• The stock touched a 52-week low of ₹400 on Feb 17, 2026, before reversing higher on improving margins.
• Q1FY27 revenue grew 49% YoY with 39% SSSG and EBITDA margins up 273 bps, despite higher depreciation from new stores.
• Analysts project 75–80 new stores per year and a target price of ₹945, implying a multi-quarter growth story and a BUY rating.

bluestone share price momentum is in focus as Bluestone Jewellery and Lifestyle, a digital-first jewellery retailer focused on contemporary and design-led jewellery across gold, diamond and studded categories, navigates a volatile market. The company operates 352 stores in 139 cities across 28 states and derives 95% of its manufacturing in-house. It issued equity shares at ₹517 per share in its IPO and made its stock market debut on August 19, 2025. A series of price moves have followed: the stock touched a 52-week low of ₹400 on February 17, 2026, and an intraday high of ₹872.60 on the BSE. As of 10:49 AM, Bluestone was trading at ₹827, up about 14% while the benchmark index fell 0.82%.

BlueStone's strong in-house manufacturing strength – about 95% – helps it navigate raw-material volatilities amid gold price swings. The company operates a nationwide footprint with 352 stores across 139 cities in 28 states. This scale, combined with a digital-first approach, positions Bluestone to capitalize on festival-season demand and the growing Indian middle class's appetite for design-led jewellery. The IPO price of ₹517 per share remains a historical anchor point for the stock's baseline valuation.

Bluestone Share Price Momentum: What The Last 2 Days Revealed

The bluestone share price has surged about 43% in the last two trading sessions, signaling a strong short-term momentum that outpaced the broader market during a volatile phase. The intraday activity reflected renewed interest, with a new intraday high of ₹872.60 on the BSE and the stock trading around ₹827 at 10:49 AM, up 14% as the benchmark index fell. The rally occurred against a backdrop of improving earnings signals and continued optimism on same-store-sales growth (SSSG) and expansion plans.

Contributing factors include the stock's volume action – the average trading volume jumped 18-fold in the recent period, with 24.9 million equity shares changing hands across NSE and BSE, representing roughly 16.3% of total equity. This participation suggests supply-demand shifts rather than isolated trades. The two-day run aligns with a broader rally in the past month where Bluestone share price rose roughly 67% against a flat Sensex backdrop, underscoring a renewed risk appetite among retail investors.

Bluestone IPO Listing: From Debut To The Current Rally

BlueStone made its stock market debut on August 19, 2025, at an issue price of ₹517 per share. Since then, the stock has experienced a wide range of price action, including a 52-week low of ₹400 in February 2026. The current momentum is part of a broader trend of renewed interest in consumer-discretionary names as earnings momentum improves, and the company continues to push for growth through store additions and stronger same-store performance.

From an ownership perspective, the company's cap table shows a significant retail participation base, with retail investors such as Ganesh Krishnan and Kamath Associates each holding roughly around 1% stakes as of the end of Q1 FY27, and other major shareholders including Sunil Kant Munjal continuing to hold a stake that represents a few percent of the company. Munjal held 3.65% (about 5.56 million shares) at end-June 2026, after selling 85,000 shares in the June quarter and previously holding 5.65 million shares (3.71%) at the end of March 2026 quarter.

Bluestone Quarterly Results: Q1FY27 Highlights And Margin Trends

BlueStone's Q1 FY27 results showcased resilient revenue growth and improving profitability metrics despite ongoing investments in the store network. Revenue grew 49% year-on-year, supported by a strong SSSG momentum of 39% YoY, compared with 34% in Q4 FY26 and 18% in Q1 FY26. EBITDA margin improved by 273 basis points year-on-year, reflecting higher gross margins and operating leverage, even as depreciation rose 24% YoY due to new store additions, leading to an adjusted net loss of ₹12.9 crore versus ₹51.1 crore in Q1 FY26.

The management continues to guide for around 30% SSSG in the near term and 20% revenue growth through store additions, with analysts factoring in approximately 75–80 new stores added per year and an EBITDA margin target of around 14% for FY28E. The elevated growth expectations have prompted revisions to earnings estimates for FY27 and FY28, with a target price around ₹945 and a 25x FY28E EV/EBITDA multiple, which underpins a Buy rating from several analysts.

Store Growth, Guidance And Analyst Outlook

Analysts see Bluestone's growth engine sustained by a robust store network expansion alongside improvements in same-store performance. The company’s guidance of roughly 20% revenue growth through store openings aligns with an expectation of about 75–80 new stores annually, while the EBITDA margin target sits near 14% by FY28E. The Q1FY27 results have reinforced this outlook, supporting revised earnings estimates for FY27 and FY28. With a new generation of customers embracing design-forward jewellery, Bluestone's omnichannel strategy is positioned to capitalize on rising discretionary demand.

To understand the data deeper and tailor investment decisions, investors can consult Swastika's Sarthi AI stock assistant for context-rich stock analysis across all instruments. Swastika's Sarthi AI stock assistant can help quantify risk and refine entry points aligned with individual risk tolerances.

Price Data Snapshot: 52-Week Low, Intraday High And Volume

The price action demonstrates volatility but also a clear upward re-rating in the Bluestone share price narrative. A table below summarises the key data points discussed above:

Metric	Value	Date
52-Week Low	₹400	Feb 17, 2026
Intraday High (BSE)	₹872.60	Aug 2025
Price At 10:49 AM	₹827	Jul 22, 2026
Two-Day Rally	43%	Jul 2026
One-Month Rally	67%	Jul 2026
Avg Daily Volume (NSE+BSE)	24.9 million shares	Jun 2026
Share Of Total Equity Traded	16.3%	Jun 2026

Analyst Outlook: Valuation, Targets And What Comes Next

Analysts have been revising earnings estimates upward for FY27 and FY28, reflecting stronger-than-expected revenue growth from a broader footprint and improved SSSG. A common consensus target price is around ₹945, implying a valuation of roughly 25x FY28E EV/EBITDA. The Buy rating is supported by the expectation of sustained expansion, both in terms of stores and revenue growth, as well as improving EBITDA margins heading toward the FY28E target. Investors should watch for potential catalysts in store openings (75–80 per year anticipated) and any further demonstration of margin resilience in the face of gold price volatility.

Frequently Asked Questions

When did Bluestone IPO Listing debut on the stock market?

Bluestone made its stock market debut on August 19, 2025.

What is Bluestone's 52-week low, and when was it touched?

The 52-week low was ₹400, touched on February 17, 2026.

How has the Bluestone share price moved recently?

The stock surged about 43% over the last two trading days and rose about 67% in the past month.

What were Bluestone's Q1FY27 results?

Q1FY27 revenue grew 49% YoY with 39% same-store-sales growth; EBITDA margin rose 273 bps YoY, while depreciation rose 24% due to store additions; adjusted loss was ₹12.9 crore vs ₹51.1 crore in Q1 FY26.

What is Analysts' valuation and store-growth outlook for Bluestone?

Analysts have revised earnings higher with a target around ₹945, roughly 25x FY28E EV/EBITDA, assuming 75–80 new stores per year; Buy ratings are common.

Conclusion

For the retail investor, Bluestone's journey from its IPO listing to the current rally underscores the duality of growth and risk in consumer discretionary names. While the Bluestone share price has recouped losses from the 52-week low and climbed on stronger quarterly trends, the path forward depends on maintaining SSSG momentum and delivering on store expansion plans. The practical takeaway is to balance the upside potential with a disciplined entry approach, using a risk framework that accounts for commodity price cycles and evolving capital expenditure needs.

Open your trading and demat account here

Reference :

1 : Business Standard

Key Takeaways

• Q1FY27 revenue rose to ₹1,880 crore with consolidated net profit of ₹33 crore, down 21.7% YoY from ₹42 crore.
• The quarter added 146 stores to reach 5,476 outlets; franchise stores nearly 12% of the network.
• Nomura maintains Buy with a Rs 1,190 target; valuation around 24x FY27 EV/EBITDA, with implied 30x FY27 and 22x FY28 EV/EBITDA.
• MedPlus Health share price fell 15.83% to ₹667.95 after the results, reflecting cost and margin pressures.

If you're tracking medplus health share price, Q1FY27 results reveal a mixed bag of revenue growth and margin headwinds as MedPlus Health Services presses ahead with rapid store expansion. Revenue rose to ₹1,880 crore, up 21.9% YoY, while consolidated net profit came in at ₹33 crore, down 21.7% from ₹42 crore in the year-ago quarter. These figures set the stage for assessing whether the expansion-led model can translate into sustainable earnings, especially as costs rise in non-pharmacy overhead and salaries.

The quarter also showed a robust topline performance across segments: gross profit rose 14% YoY, while gross margin declined by 163 basis points. Operating EBITDA declined 11% YoY, and was about 29% below Nomura's estimates. The company expanded its store network by adding 146 stores in the quarter, taking the total to 5,476 outlets, with franchise stores accounting for nearly 12% of the network. Franchise revenue contribution rose to 5.4% of pharmacy revenue in Q1FY27 from 2.5% a year ago, underscoring a gradual shift toward a mixed model with more franchised avenues.

MedPlus Health Share Price Momentum After Q1FY27 Results

Revenue growth remained healthy at 22% YoY, with branded pharma leading growth at 20%, branded non-pharma at 17%, and private label pharma at 30%. Mature pharmacy network grew 12% YoY, while private label growth was 2% YoY. Private label contribution to own-store revenue stood at 11.5% in Q1FY27, down from 13.4% in Q1FY26, contributing to a gross margin decline attributed to lower private label contribution and a higher share of franchise sales, which weighed on margins by roughly 120 basis points and around 50 basis points, respectively.

MedPlus Health Share Price Valuation And Nomura Target Price Insights

Valuation context places MedPlus at around 24x FY27 estimated EV/operating EBITDA. Nomura's implied multiples are 30x FY27 EV/operating EBITDA and 22x FY28 EV/operating EBITDA. The broker's Buy rating comes with a target price of Rs 1,190, reflecting the long‑term growth potential from its expanding store network and stable supply of branded products.

MedPlus Health Share Price Growth Drivers Across Segments And Store Model

Segment growth data show branded pharma up 20%, branded non-pharma up 17%, and private label pharma up 30%. Franchise revenue contribution, though still modest, has risen to 5.4% of pharmacy revenue in Q1FY27 from 2.5% a year ago. The mature network's 12% YoY growth indicates resilience even as new store openings drive near-term top-line momentum. Private label growth of 2% suggests some rebalancing in product mix, while private label contribution to own-store revenue stands at 11.5% in Q1FY27 versus 13.4% in Q1FY26.

MedPlus Health Share Price Margin Pressures And Cost Structure

Pharmacy salary expenses rose 30% YoY, with per-store salary increases of 14% on a per-store basis. Non-pharmacy overhead climbed 34% YoY, while store expansion added 146 stores in the quarter. The combination of higher payroll and overhead has contributed to margin headwinds, with gross margin down 163 basis points and operating EBITDA down 11% YoY–about 29% below Nomura's estimates.

Management and investors will watch whether rapid store expansion can translate into sustainable earnings growth. Capex plans include two Hyderabad projects. One is a food park with about ₹40 crore of capex, and the other is a concierge health and wellness facility with about ₹115 crore, including around ₹90 crore in capex. These investments signal growth acceleration but require subsequent improvement in profitability to sustain earnings power.

MedPlus Health Share Price Capex Plan And Growth Path For Retail Investors

The focus remains on translating store expansion into earnings leverage over time. The company added 146 stores in the quarter, increasing the total store network to 5,476 outlets. The franchise share, at nearly 12% of the network, and the franchise revenue contribution of 5.4% of pharmacy revenue, highlight a diversified growth engine beyond traditional company-operated stores. The longer-term growth potential stems from a balanced mix of branded and private-label products, supported by capex in Hyderabad projects and wellness facility expansions.

For deeper stock-level insights, consult Swastika's Sarthi AI stock assistant.

Frequently Asked Questions

What were MedPlus Health's Q1FY27 revenue and net profit?

Revenue was ₹1,880 crore and consolidated net profit was ₹33 crore for Q1FY27.Net profit declined 21.7% YoY from ₹42 crore in Q1FY26.

How did MedPlus Health's Q1FY27 revenue grow YoY?

Revenue grew 21.9% YoY to ₹1,880 crore, up from ₹1,543 crore in Q1FY26.

How many stores were added in Q1FY27 and what is the total store network?

146 stores were added in the quarter, taking the total store network to 5,476 outlets. Franchise stores accounted for nearly 12% of the network.

What is Nomura's view on MedPlus Health and its target price?

Nomura maintained Buy rating with a target price of Rs 1,190. Valuation context shows around 24x FY27 estimated EV/EBITDA; Nomura's implied multiples are 30x FY27 EV/EBITDA and 22x FY28 EV/EBITDA.

What capex plans has MedPlus announced?

MedPlus announced capex for two Hyderabad projects. Food Park capex around ₹40 crore and Concierge health and wellness facility capex around ₹115 crore, including about ₹90 crore in capex.

What were the segment growth figures for MedPlus Health in Q1FY27?

Segment growth: branded pharma 20%, branded non-pharma 17%, private label pharma 30%. Mature pharmacy network growth was 12% YoY; private label growth was 2% YoY. Private label contribution to own-store revenue stood at 11.5% in Q1FY27 vs 13.4% in Q1FY26.

Conclusion

In the near term, MedPlus Health's expansion-led growth faces margin pressure from higher salaries and overhead, even as topline growth remains robust. For retail investors, the key question is whether the higher store count and a diversified revenue mix can translate into sustainable earnings growth at current valuations, which sit around 24x FY27 EV/EBITDA based on Nomura's framework. A disciplined approach to entry–focused on margin improvement and cash flow generation–may help investors capitalize on the long-run potential of a 5,476-store network with a growing private-label share.

Next steps for investors: monitor margin recovery, store-level profitability, and capex efficiency while using tools like Swastika's Sarthi AI stock assistant for ongoing analysis; with the right discipline, the long-term growth story could unlock substantial upside as the network scales.

Open your trading and demat account here

Reference :

1 : Economictimes

Key Takeaways

• On July 22, 2026, Nifty and Sensex slipped about half a percent as three catalysts converged, impacting the nifty pharma stock list.
• Nifty 50 closed at 24,048 and Sensex at 76,988, with intraday lows of 24,008.20 and 76,851 respectively.
• Nifty Pharma index declined 1.32% in early trade at 25,747.60, with all 19 pharma stocks trading lower.
• Brent crude rose to $91.51 and WTI to $84.64 as tariff talk and geopolitical tensions weighed on sentiment.

Three catalysts collided on July 22, 2026, pushing Indian equities lower as the nifty pharma stock list wobbled under tariff talk and global tensions. The day unfolded with a sequence of events that tested risk appetite and exposed sector-specific vulnerabilities. For retail investors, understanding these drivers helps calibrate exposure to the nifty pharma stock list and other risk assets.

Key Market Snapshot For July 22, 2026

Metric	Value
Nifty 50 Close (July 22)	24,048
Sensex Close (July 22)	76,988
Nifty Smallcap 250 Movement	Down About 1%
Nifty Midcap 150 Movement	Down About 0.68%
Nifty Pharma Index (Early Trade)	Down 1.32% at 25,747.60
Pharma Constituents	All 19 trading lower
Nifty 50 Intraday Low	24,008.20 (as of 10:10 am)
Sensex Intraday Low	76,851 (as of 10:10 am)
Brent Crude	US$91.51 per barrel
WTI Crude	US$84.64 per barrel
US Generics Tariffs	Zero tariffs for two years; 100% in year three; 200% thereafter

Geopolitical context added to price action: US CENTCOM completed the 11th night of strikes on Iran, targeting military operations centres, maritime capabilities, aircraft hangars, drone storage facilities and logistics infrastructure. The broader war effort against Tehran is shown as costing US$37.5 billion so far.

Within the market, the direction was also shaped by sector breadth: the Nifty Smallcap 250 moved lower by about 1%, while the Nifty Midcap 150 slipped roughly 0.68%. The Nifty Pharma index itself faced pressure, with all 19 constituents trading in the red.

Under the proposed US framework for generics, imported drugs will continue to attract zero tariffs for the next two years. However, tariffs could rise to 100% in the third year and 200% thereafter, to incentivise US-based production facilities. This policy backdrop adds to the risk premium in the pharma space and helps explain the broad-based weakness in the nifty pharma stock list.

To illustrate the context of the day, consider the currency/commodity backdrop: Brent at $91.51 and WTI at $84.64 per barrel. The intraday market narrative also included tension related to Iran's strikes against US facilities in Bahrain, Kuwait and Jordan – a reminder that geopolitics remain a potent driver of risk-taking, even in a diversified domestic equity complex.

Fresh Strikes From US And How They Affected Indian Markets

The three reasons highlighted for the market fall are anchored in the same three forces: Fresh Strikes from US, Crude Rises Again, and Pharma's Tariff Threat. The immediate market reaction was risk-off across equities, with cyclical and defensives alike feeling the pull. The intraday movement showed the Nifty 50 dropping to as low as 24,008.20, and the Sensex slipping to 76,851 at around 10:10 am, underscoring how quickly sentiment shifted when geopolitics intersects energy prices and policy signals.

In the pharmaceutical space, the pressure was sharper: the nifty pharma stock list faced a crosshair of tariff uncertainty and global pricing dynamics. The Nifty Pharma index fell 1.32% in early trade, with all 19 constituents trading in the red, even as several large blue-chips in the sector kept headlines active for longer-term investors. The day’s data make clear that pharma risk is not isolated to one stock; it is a sector-wide reflection of policy risk and global price movements.

Oil Prices Rise Again: What It Means For Indian Markets

Oil remains a key variable for Indian macro and corporate earnings. On July 22, Brent crude traded at $91.51 per barrel, up 0.55%, while US WTI crude rose 0.36% to $84.64 per barrel. A higher oil regime tends to flow through to energy costs, inflation expectations and debt-servicing costs, which can compress equity valuations, especially in growth-sensitive sectors such as technology and consumer discretionary. For the pharma space, higher energy costs indirectly influence manufacturing and supply chain economics, while for the overall market, crude's rise can widen risk-off bets when geopolitics loom large.

The fresh strikes from US actions in the Middle East, combined with the persistent energy complex, contribute to a volatile backdrop for the nifty pharma stock list. The day’s intraday dynamics illustrate how quickly sector leadership can shift from one area to another as macro variables interact with policy signals. Investors should watch how energy prices feed into global inflation expectations and domestic earnings for pharma companies and suppliers along the value chain.

Pharma's Tariff Threat And Its Implications For The Nifty Pharma Stock List

The tariffs on imported generic medicines embody a policy risk that could reprice the pharma sector. The proposed framework allows zero tariffs on generics for the next two years, but tariffs could rise to 100% in year three and eventually 200% thereafter. The policy aims to incentivise pharmaceutical manufacturers to establish production facilities in the US, a move that could alter global supply chains and pricing dynamics. For the nifty pharma stock list, this could either pad margins for some players that are well positioned to localize production or squeeze margins for those relying on import- or export-led models. Investors should consider how each company’s supply chain and hedging strategies are positioned to respond to tariff risk and the direction of US policy on generics.

As a backdrop, the day’s price action in early trade – with the nifty pharma index down 1.32% at 25,747.60 and all 19 constituents in the red – underscores the sensitivity of Indian pharma players to global policy signals. The sensitive nature of policy risk means investors should prepare for the possibility of further volatility around tariff announcements and blue-sky policy proposals, particularly for players with higher import exposure or greater dependence on US pricing.

Stocks To Watch In The Nifty Pharma Stock List

Within the nifty pharma stock list, the watchlist often includes large-cap names whose stock price movements can influence the broader sector. Consider the stock price of sun pharma, cipla limited stock price, lupin ltd stock price, aurobindo pharma stock price, and dr reddy's stock. These five names can provide a sense for sector breadth and for how policy changes or global cues might translate into the price action you observe in the Nifty Pharma index. For real-time insights into these names, you can consult Swastika's Sarthi AI stock assistant: Swastika's Sarthi AI stock assistant.

Frequently Asked Questions

What caused the market to slide on July 22, 2026?

The day was driven by three catalysts: Fresh Strikes from US, Crude Rises Again, and Pharma's Tariff Threat, amid geopolitical tensions and energy dynamics that raised risk-off concerns.

How did the Nifty Pharma stock list perform on that day?

The Nifty Pharma index declined 1.32% in early trade to 25,747.60, with all 19 pharma constituents trading in the red.

What were the intraday lows for Nifty 50 and Sensex on July 22, 2026?

Nifty 50 intraday low was 24,008.20 and Sensex intraday low was 76,851 as of 10:10 am.

What tariffs were proposed for US generic drugs?

Zero tariffs for the next two years, then tariffs could rise to 100% in year three and 200% thereafter, to incentivise US-based production facilities.

Where can investors get deeper stock insights into the Nifty Pharma stock list?

Explore deeper analysis with Swastika's Sarthi AI stock assistant:Swastika's Sarthi AI stock assistant.

Conclusion

July 22, 2026 was a teaching moment for traders and retail investors alike. The nifty pharma stock list did not move in isolation; it reflected a confluence of policy risk, geopolitical tension and energy price dynamics that can quickly alter risk appetites for the sector and the broader market. The practical takeaway is to treat sector-specific headlines and macro signals as coupled risk drivers, rather than standalone triggers. Investors should adjust their risk budgets, ensure proper diversification, and maintain a framework for monitoring pharma policy signals relative to energy and geopolitical developments.

As a next step, build a simple mental model: scenario planning around three catalysts–Fresh Strikes From US, Crude Rises, and Pharma Tariff Threat–and use hedges or position-sizing to manage potential drawdowns in your portfolio. For ongoing stock analysis, the Sarthi AI stock assistant can help you compare the nifty pharma stock list’s components and test ideas before taking action.

Open your trading and demat account here

Reference :

1 : Ndtvprofit

Key Takeaways

• crisil share price moved to Rs 4452.25 after a 3.49% gain on Q2 CY26 results.
• Consolidated net profit rose 26.2% YoY to Rs 216.5 crore on income from operations of Rs 1,075.4 crore, up 27.6%.
• crisil ratings segment revenue grew 21.4% YoY to Rs 305.12 crore in Q2 2026.
• Crisil is majority owned by S&P Global and is investing in GenAI to drive future growth.

Crisil Share Price Snapshot And Q2 CY26 Market Reaction

Investors watch crisil share price move to Rs 4452.25 and rise 3.49% after Crisil reported a robust Q2 CY26 performance. Consolidated net profit rose 26.2% YoY to Rs 216.5 crore on a 27.6% increase in income from operations to Rs 1,075.4 crore in Q2 CY26 as compared with Q2 CY25. Profit before tax stood at Rs 279.8 crore, up 24.4% YoY; net foreign exchange movement resulted in a loss of Rs 8.2 crore in Q2 2026 vs a loss of Rs 6.6 crore in Q2 2025. The market reaction reflects a mix of earnings momentum and a continued shift toward services-driven analytics in Crisil's portfolio.

Crisil Earnings And Revenue Growth In Q2 CY26

Consolidated net profit: Rs 216.5 crore; up 26.2% YoY. Income from operations: Rs 1,075.4 crore; up 27.6% YoY. Profit before tax: Rs 279.8 crore; up 24.4% YoY. Net foreign exchange movement: loss of Rs 8.2 crore in Q2 2026 vs a loss of Rs 6.6 crore in Q2 2025. These figures are crisil earnings for the quarter and highlight Crisil's ability to grow across its core and new lines of business, even in a volatile macro environment.

Crisil Ratings Momentum And Segment Growth

crisil ratings segment revenue grew 21.4% YoY to Rs 305.12 crore in Q2 2026, underscoring continued demand for rating services across sectors. Crisil Coalition Greenwich saw momentum in corporate and investment banking and continued traction in commercial banking. Crisil Intelligence saw continued demand for data analytics, consulting, and credit and risk solutions. Together, these pillars illustrate Crisil's diversified revenue mix and its ability to harvest growth across traditional ratings and advanced analytics.

GenAI Momentum And Crisil's Growth Outlook

Amid a volatile macroeconomic and geopolitical environment, Crisil has reinforced its GenAI focus to convert opportunities into long-term growth.

According to Amish Mehta of Crisil, “Our Q2 2026 performance reflects continued growth momentum and disciplined execution of our strategic priorities. Despite a volatile and challenging macroeconomic and geopolitical environment, we delivered growth across both our domestic and international businesses. As clients step up investments in GenAI, we are focused on leveraging our domain-led GenAI capabilities and future-ready talent to convert this opportunity into long-term growth.”

Reference :

1 : Business Standard

This is a signal that the strategy is not just about short-term gains but building a scalable platform for analytics-led growth that leverages GenAI across Crisil's multiple business lines.

Crisil Ownership And Global Backing

Crisil is majority owned by S&P Global, a fact that anchors its credibility and access to global methodologies and markets. The company operates as a global, insights-driven analytics firm with capabilities spanning Crisil Ratings, Crisil Intelligence, Crisil Coalition Greenwich, and Crisil Integral IQ; with activities across the Americas, Asia-Pacific, Europe, Australia and the Middle East. This global backing helps Crisil expand its footprint while maintaining rigorous, domain-specific research and risk assessment capabilities.

Credit Market Trends And The Big Picture For Retail Investors

Bank credit remained robust at 17.7% as of May 2026 compared to 9.0% as of May 2025, suggesting a supportive environment for Crisil's growth in financial services analytics and credit risk solutions. Credit to large corporates rebounded to 14.4%, while that to NBFCs remained the key driver of services sector credit growth. Yields on corporate bonds remained elevated, which contributed to a 25.7% YoY decline in issuance by value in Q2 2026; the number of issuers was down 15.3%; issuances were down 12.9%. These macro trends influence Crisil's advisory and ratings workflows as clients recalibrate risk and funding strategies. For investors, this backdrop underscores the continued relevance of Crisil's analytics in evaluating credit quality, ratings, and risk across sectors.

Stock Price Momentum, Market Signals, And Investor Takeaways

From a retail-investor perspective, Crisil's Q2 CY26 results reinforce a narrative of resilience and growth in analytics-driven services. The 3.49% rise in the crisil share price to Rs 4452.25, supported by a 26.2% YoY profit uplift and a 27.6% rise in income from operations, suggests the market is pricing in Crisil's ability to monetize GenAI opportunities and expand its data-intensive offerings. The strong performance of the ratings segment (21.4% YoY growth) adds further validation that Crisil's core capabilities remain in high demand even as the business mix evolves. A diversified earnings profile, plus a credible ownership structure with S&P Global, positions Crisil to weather macro headwinds and capitalize on GenAI-driven analytics opportunities. As always, a disciplined approach to growth, balance sheet quality, and a clear strategic roadmap are essential for long-term investors. If you want a deeper, data-driven read on Crisil's growth drivers and how to map them to your portfolio, consider using Swastika's Sarthi AI stock assistant for institutional-grade stock research [link provided below].

For a structured, side-by-side view of the quarter's key metrics, you can refer to the summary table below. It highlights the headline figures and YoY changes that underpin the stock's price action. This snapshot helps investors compare Crisil's Q2 CY26 performance with the prior-year period and understand where the company is gaining momentum across its business lines.

Metric	Q2 CY26	YoY Change
Consolidated net profit	Rs 216.5 crore	+26.2%
Income from operations	Rs 1,075.4 crore	+27.6%
Profit before tax	Rs 279.8 crore	+24.4%
Net forex movement	loss Rs 8.2 crore	–
Ratings services segment revenue	Rs 305.12 crore	+21.4%

Key macro and sector trends to watch include robust bank credit growth, elevated corporate-bond yields, and continued demand for data analytics and risk-solutions. Crisil's multi-pronged growth engine–ratings, analytics, intelligence, and Greenwich-relevant services–positions it to benefit from both conventional rating workflows and the GenAI-enabled analytics frontier. If you’re evaluating Crisil as a potential investment, consider the stock's price reaction in light of these fundamentals and how GenAI investments could translate into longer-term earnings acceleration.

Frequently Asked Questions

What were Crisil's Q2 CY26 earnings and revenue?

Consolidated net profit: Rs 216.5 crore; Income from operations: Rs 1,075.4 crore; Year-over-year changes were +26.2% and +27.6% respectively. Profit before tax was Rs 279.8 crore, up 24.4% YoY.

What is Crisil's relationship with S&P Global?

Crisil is majority owned by S&P Global.

What was Crisil's stock price move after the Q2 CY26 results?

Crisil share price moved to Rs 4452.25 after a 3.49% gain following the Q2 CY26 results.

How did Crisil's Ratings segment perform in Q2 2026?

crisil ratings segment revenue grew 21.4% YoY to Rs 305.12 crore in Q2 2026.

What GenAI-related guidance did Crisil provide for growth?

Amid GenAI momentum, Crisil highlighted leveraging domain-led GenAI capabilities and future-ready talent to convert opportunities into long-term growth, as stated by Crisil's leadership.

Conclusion

In a market where GenAI is turning from ambition into execution, Crisil’s Q2 CY26 results offer a practical signal for retail investors: growth across traditional analytics, ratings, and new data-driven services remains intact, and the company is actively harnessing GenAI to broaden its value proposition. The crisil share price reaction reflects this mix of earnings momentum and strategic positioning, underpinned by S&P Global ownership that lends credibility and scale to Crisil’s model. The next step for a thoughtful investor is to test this narrative against a disciplined framework–check margins, segment growth, and the potential uplift from GenAI-enabled offerings as you assess a long‑term allocation.

Open your trading and demat account here

Key Takeaways

• indiamart intermesh share price moved lower despite a 12.2% rise in Q1 net profit to Rs 172 crore.
• Revenue from operations rose 11.4% to Rs 414 crore, with web services contributing Rs 375.9 crore and accounting software Rs 38.5 crore.
• Analysts show mixed calls: 10 Buy, 2 Hold, 6 Sell; average 12-month target Rs 2,095.11 implying 14.9% upside.
• Intraday moves included opening at Rs 1,907, intraday low Rs 1,773, and around Rs 1,810.20 at 10:10 AM.

Indiamart Intermesh Share Price After Q1FY27: What Moved The Market

indiamart intermesh share price movements often reflect a tug-of-war between earnings momentum and market sentiment. In Q1FY27, Indiamart Intermesh Ltd reported a consolidated net profit rise of 12.2% to Rs 172 crore for the June quarter, while revenue from operations climbed 11.4% to Rs 414 crore. Yet, the indiamart intermesh stock tumbled over 7% in intraday trades, underscoring how investors weigh growth against valuation and guidance. The stock's intraday action contrasted with the Nifty 50's modest 0.59% decline, highlighting dispersion in stock-specific moves.

Time (IST)	Price (Rs)	Change
Open	Rs 1,907	−0.57%
Intraday Low	Rs 1,773	−7.56%
10:10 AM	Rs 1,810.20	−5.62%

Q1FY27 Earnings And Margin Data: A Closer Look

The quarter showed a 12.2% rise in consolidated net profit to Rs 172 crore to Rs 172 crore, up from Rs 153.5 crore in the year-ago period. Revenue from operations rose 11.4% to Rs 414 crore, versus Rs 372 crore a year ago. EBITDA (GU) grew 9.7% YoY to Rs 147 crore, up from Rs 134 crore, while EBITDA margin stood at 35.4%, slightly below the 35.9% seen in the prior year.

Other income increased to Rs 107 crore from Rs 92 crore, contributing to the overall earnings strength. These metrics reflect a company that is expanding top-line growth while maintaining a stable margin profile despite some expansion in other income streams.

Revenue Mix And Segment Focus: Web Services And Accounting Software

Revenue from Web and related services was Rs 375.9 crore, while accounting software services contributed Rs 38.5 crore. This mix highlights the company’s reliance on its Web services platform, even as software services provide a steady contribution to profitability. The composition underscores the importance of maintaining a robust platform ecosystem to sustain growth in a competitive B2B marketplace.

The market mood around indiamart intermesh stock also reflected an intra-day dynamic: 0.11 times its 30-day average traded volume, and RSI stood at 51.56, indicating neither overbought nor oversold territory in that moment.

Out of 18 analysts tracking the company, 10 maintained a Buy, 2 held, and 6 recommended Sell, according to Bloomberg data. The average 12-month consensus price target of Rs 2,095.11 implies an upside of 14.9% from current levels, suggesting some upside potential anchored in earnings growth and market positioning.

For deeper stock insights, explore Swastika's Swastika's Sarthi AI stock assistant.

What The Market Is Saying About The Indiamart Intermesh Share Price Target

The collective consensus price target provides a rough gauge for upside potential, with the 12-month target at Rs 2,095.11 signaling about a 14.9% appreciation from current levels. Investors should note that this target can shift as earnings trajectories, competitive dynamics, and macro conditions evolve, particularly in the Indian B2B e-commerce landscape where Indiamart Intermesh operates.

Why The Q1FY27 Results Look Mixed On The Surface

Even though profit improved and revenue grew, investors may be weighing valuation and future growth momentum against the current share price. The 12.2% profit rise is meaningful, but it must be interpreted with margins that held steady (EBITDA margin at 35.4% vs 35.9% YoY) and with the understanding that other income rose to Rs 107 crore from Rs 92 crore–an element that could reflect one-off or non-operating gains. The share price reaction, therefore, may reflect a combination of valuation expectations, market volatility, and the pace of growth in Web services and software offerings.

Frequently Asked Questions

What happened to the indiamart intermesh stock after the Q1FY27 results?

The indiamart intermesh stock moved lower, tumbling over 7% intraday even as Q1FY27 consolidated net profit rose 12.2% to Rs 172 crore and revenue grew 11.4% to Rs 414 crore.

What were the Q1FY27 numbers for Indiamart Intermesh?

Q1FY27 consolidated net profit rose 12.2% to Rs 172 crore; revenue from operations climbed 11.4% to Rs 414 crore; EBITDA stood at Rs 147 crore with an EBITDA margin of 35.4%.

What is the indiamart intermesh share price target according to the latest consensus?

The average 12-month consensus price target is Rs 2,095.11, implying an upside of 14.9% from current levels.

How did analysts rate Indiamart Intermesh after the results?

Out of 18 analysts, 10 recommended buying, 2 held, and 6 suggested selling the stock.

What were the intraday price moves mentioned in the report?

The stock opened at Rs 1,907, fell to as low as Rs 1,773, and was around Rs 1,810.20 at 10:10 AM, showing a 5.62% decline at that time.

Conclusion

Disclaimer: This analysis uses the numbers reported for Q1FY27 and the associated market data as plain market facts. Investors should conduct their own due diligence and consider consultation with a financial advisor before trading decisions.

Open your trading and demat account here

Reference :

1 : Ndtvprofit